pharma · high blood pressure · increased blood clotting
APREMEDA s.r.o
s.r.o.
APREMEDA s.r.o trial registry — 5 ClinicalTrials.gov studies with program phase, status, and indication context.
EU HQ
2020 Founded
18 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Founded
- 2020
- Employees
- 18
- Programs
- 5
- Drugs
- 16
- Patents
- 0
APREMEDA s.r.o clinical trials
Registry index of 5 ClinicalTrials.gov studies linked to APREMEDA s.r.o programs — each row shows trial ID, program name, phase, status, and indication.
APREMEDA s.r.o trial registry — 5 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for APREMEDA s.r.o.
Trial registry
-
CTIS ↗ -
CTIS ↗ - 2024-511448-17-02CTIS ↗
CPA 556-24
healthy subjects, It is used in conditions with decreased immunity to enhance it e.g. in case of recurrent and chronic viral infections.
-
CTIS ↗ - 2024-519920-26-00CTIS ↗
A pilot for UDCA causes a reduction in chol…
UDCA causes a reduction in cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and reducing cholesterol secretion into the bile. Presumably, cholesterol gallstones are gradually dissolved by dispersion of the cholesterol and formation of liquid crystals.